Catalyst Pharmaceuticals (CPRX) FCF Margin (2018 - 2026)
Catalyst Pharmaceuticals' (CPRX) quarterly FCF Margin came in at 39.87% in Q1 2026, down 259.0% YoY from 25.07% in Q1 2025, and up 35.64% on a QoQ basis from 29.39% in Q4 2025.
Catalyst Pharmaceuticals (CPRX) FCF Margin (2018 - 2026) Analysis & Trends
Catalyst Pharmaceuticals (CPRX) has 9 years of FCF Margin data on file, last reported at 39.87% in Q1 2026.
- Quarterly FCF Margin fell 259.0% year-over-year to 39.87% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 34.86% (down 1518.0% YoY) and the FY2025 annual result came in at 35.42%, down 1324.0% from the prior year.
- FCF Margin advanced to 39.87% in Q1 2026, from 29.39% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 72.15% in Q3 2022 to a low of 14.05% in Q1 2023.
- A 5-year average of 42.3% and a median of 43.88% in 2023 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2024 — FCF Margin soared 2137 bps — and 2025, when it slumped 3456 bps.
- Tracing CPRX's FCF Margin over 5 years: stood at 65.96% in 2022, then fell by 24 bps to 50.25% in 2023, then decreased by 1 bps to 49.91% in 2024, then sank by 41 bps to 29.39% in 2025, then soared by 36 bps to 39.87% in 2026.
- The last three FCF Margin figures came in at 39.87% (Q1 2026), 29.39% (Q4 2025), and 21.86% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,594.17% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 70.82% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.62% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -22.35% |
| 10 | Catalyst Pharmaceuticals | 3.85 Bn | 3.09 Bn | 134.92 Mn | 39.87% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 39.87% |
| Dec 31, 2025 | 29.39% |
| Sep 30, 2025 | 21.86% |
| Jun 30, 2025 | 48.63% |
| Mar 31, 2025 | 42.46% |
| Dec 31, 2024 | 49.91% |
| Sep 30, 2024 | 56.42% |
| Jun 30, 2024 | 52.26% |
| Mar 31, 2024 | 32.21% |
| Dec 31, 2023 | 50.25% |
| Sep 30, 2023 | 43.88% |
| Jun 30, 2023 | 30.88% |
| Mar 31, 2023 | 14.05% |
| Dec 31, 2022 | 65.96% |
| Sep 30, 2022 | 72.15% |
| Jun 30, 2022 | 49.31% |
| Mar 31, 2022 | 19.68% |
| Dec 31, 2021 | 49.95% |
| Sep 30, 2021 | 60.19% |
| Jun 30, 2021 | 43.10% |